Develops siRNA drugs for rare blood diseases and cardiovascular conditions.
Jun 2026Revenue $615K/yrExpenses $68.9M/yr
No trendCash runway ≈ 1.7 years from Jun 2026
Figures by year
When will Silence Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $615K and expenses $68.9M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $559K | $91.6M | −$91.1M |
| Dec 2024 | $43.3M | $107M | −$63.3M |
| Dec 2023 | $31.6M | $96.0M | −$64.4M |
| Dec 2022 | $21.7M | $82.7M | −$61.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.